PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
07-May-2024 Formycon invites to the Annual General Meeting on June 12, 2024 in Munich Formycon AG
07-May-2024 Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update Atopia Therapeutics
07-May-2024 Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 Biotest AG
07-May-2024 Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance Medios AG
06-May-2024 Medios AG: Constantijn van Rietschoten appointed Executive Board member for International Markets Medios AG
06-May-2024 DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2025 DocMorris AG
03-May-2024 NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA ANGLE plc
03-May-2024 Kancera meets the primary objectives of the KAND145 clinical phase I study Kancera AB
02-May-2024 Poolbeg Pharma plc - Significant POLB 001 Patent Granted in United States Poolbeg Pharma plc
02-May-2024 Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich DocMorris AG
02-May-2024 MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May MEDICLIN AG
02-May-2024 MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 MEDICLIN AG
02-May-2024 ELRIG UK Announces Profs Ijeoma Uchegbu and Marcus Schindler as Keynote Speakers at Drug Discovery 2024 Drug Discovery 2024: Connecting Minds, Transforming Science, Empowering Community will take place at ExCeL London from 2–3 October
02-May-2024 PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE Defence Therapeutics Inc.
02-May-2024 Formycon hosts conference call on the results of the first quarter 2024 Formycon AG
02-May-2024 AEVIS VICTORIA SA – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%. AEVIS VICTORIA SA
01-May-2024 TRYP THERAPEUTICS AND EXOPHARM LIMITED ANNOUNCE COMPLETION OF PLAN OF ARRANGEMENT Tryp Therapeutics Inc.
01-May-2024 ABPI respond to proposals to change the Statutory Scheme ABPI
01-May-2024 Vitruvia Medical AG: Year End results as of December 31, 2023 Vitruvia Medical AG
30-Apr-2024 Vita 34 returns to growth path in 2023 Vita 34 AG